Skip to main content
. 2016 Jul 25;34(26):3166–3174. doi: 10.1200/JCO.2016.67.6346

Fig A2.

Fig A2.

Time to disease progression (TTP) with selinexor versus TTP with last prior therapy for 41 evaluable patients. Dotted line represents greater than 1.3-fold increase in TTP with selinexor. Thirteen patients were not evaluable because of lack of prior therapy (n = 4) and not having a documented date of disease progression with last prior therapy (n = 9). DD, dedifferentiated; VEGFR, vascular endothelial growth factor receptor; WD, well differentiated.